Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06676007Recruiting
Early use of a targeted budesonide for IgA nephropathy
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
Chengdu, SichuanAges 18–75 - NCT06668181RecruitingPhase 3
Study of bimekizumab for kids with certain types of juvenile arthritis
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
CalgaryAges 2–18 - NCT06657859Enrolling by invitationPhase 2
Extended study of GLM101 for PMM2-CDG patients
This study is for people who already completed a previous trial of GLM101 for PMM2-CDG. It offers continued access to the treatment while doctors monitor safety and effects.
Minneapolis, MinnesotaAges 2 years+ - NCT06668142Recruiting
Beacon platform study for prostate surgery
This trial tests a new surgical platform called Beacon during HoLEP, a common procedure to treat enlarged prostate symptoms. It may help men with difficulty urinating due to an enlarged prostate.
Santiago, Santiago MetropolitanAges 45 years+ - NCT05761223RecruitingPhase 1/Phase 2
Study of FB849 for adults with measurable cancer lesions
This early-stage trial tests whether FB849 is safe and tolerable, how the body handles it, and whether it shows any early signs of helping cancer. You may be able to join if you’re an adult with at least one measurable tumor spot and your health tests meet study requirements.
Cleveland, OhioAges 18 years+ - NCT06658522RecruitingPhase 4
Sotatercept for right heart function in pulmonary hypertension
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
Amsterdam, North HollandAges 18–70 - NCT06668584RecruitingPhase 2
Olutasidenib to prevent cancer return after stem cell transplant
This study tests if a daily pill called olutasidenib can help keep your cancer from coming back after a stem cell transplant. It's for people with a specific IDH1 gene change and myeloid cancers like AML or MDS.
Houston, TexasAges 18–75 - NCT06634849RecruitingPhase 1/Phase 2
Study of a new drug (PTT-4256) for advanced solid tumors
This trial tests a new drug called PTT-4256 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it helps shrink or control the cancer.
Blacktown, New South WalesAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06616766RecruitingPhase 1/Phase 2
Study of YH42946 for advanced cancer with HER2 or EGFR changes
This trial tests a new drug (YH42946) in people with advanced solid tumors that have specific changes in HER2 or EGFR genes and have stopped responding to standard therapies. The drug aims to target these genetic changes to slow or shrink the cancer. Participants will be monitored closely for safety and how well the drug works.
Fairfax, VirginiaAges 18 years+ - NCT06577779RecruitingPhase 4
Testing Jornay PM for adult ADHD symptoms into the evening
This study tests if Jornay PM, a long-acting ADHD medication, helps control symptoms, focus, and emotions throughout the day and into the early evening in adults with ADHD. It is an open-label study, meaning everyone knows they are getting the medication, and then they are randomly assigned to different observation groups.
New York, New YorkAges 18–60 - NCT06558201Enrolling by invitation
Open-label extension for completers of earlier study
This trial is for people who finished a 12-week study (NCT06221852) and still meet its original requirements. It offers continued access to the study treatment.
Belmont, MassachusettsAges 18–45 - NCT06553872RecruitingPhase 2
Pirtobrutinib and CAR T-cell therapy for mantle cell lymphoma
This trial tests if adding the targeted therapy pirtobrutinib before CAR T-cell treatment (Tecartus) works better for mantle cell lymphoma that has come back or not responded to other treatments. It aims to improve outcomes for patients who are eligible for CAR T-cell therapy.
Stanford, CaliforniaAges 18 years+ - NCT06542237RecruitingPhase 1/Phase 2
Study of a new male birth control pill for healthy men
This trial tests an experimental birth control pill (YCT-529) taken daily. It aims to see if the drug can safely and effectively prevent pregnancy in healthy men who do not plan to have children in the future.
Grafton, AucklandAges 28–70 - NCT06541847RecruitingPhase 2
Testing HLX-1502 for NF1 with Plexiform Neurofibromas
This trial tests an experimental drug called HLX-1502 for people with NF1 who have a plexiform neurofibroma (a type of nerve tumor) that is growing or causing problems. It aims to see if the drug is safe and can shrink or stop the tumor from worsening.
Birmingham, AlabamaAges 12 years+ - NCT06549400Enrolling by invitationPhase 3
Study on long-term safety of mexiletine for myotonic dystrophy
This study tests if a daily capsule of mexiletine is safe and helpful over 26 weeks for people with myotonic dystrophy type 1 or 2. It's for people who finished a previous related study and want to continue treatment.
LeuvenAges 16 years+ - NCT06514534RecruitingPhase 2
Asciminib for CML with T315I mutation and ponatinib problems
This trial tests a new drug called asciminib for people with CML who have a specific genetic change (T315I) and cannot take or did not benefit from the drug ponatinib. The goal is to see if asciminib can help control the leukemia.
BordeauxAges 18–99 - NCT06480552RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT06490757RecruitingPhase 2
Testing a pill for large inflamed liver growths
This trial tests a daily pill (baricitinib) to shrink large, inflamed liver growths called inflammatory hepatocellular adenomas. It may be an option for people who have at least one growth larger than 5 cm and who are not using estrogen-containing birth control.
BobignyAges 18–65 - NCT06494111RecruitingPhase 2
Preventing neck swelling after radiation for throat cancer
This study tests two medicines—pravastatin (a statin) and a combination of pentoxifylline and Vitamin E—to see if they can prevent long-term swelling (lymphedema) and scarring in the neck after radiation therapy for throat cancer. Participants receive one of the medicines daily for 2 years, and regular scans help monitor any changes.
Houston, TexasAges 18 years+ - NCT06488625RecruitingPhase 2/Phase 3
Nicotinamide for mild to moderate ulcerative colitis
This trial tests whether a special oral form of nicotinamide (a type of vitamin B3) can help control mild to moderate ulcerative colitis. The pill is designed to release the medication in the lower part of your gut, where UC often affects. Participation involves taking the study drug and having regular checkups to see how your symptoms and inflammation respond.
Kiel, Schleswig-HolsteinAges 18–80 - NCT06464588RecruitingPhase 1
Testing safety of newborn stem cells for dilated cardiomyopathy in young adults and children
This study tests whether a single intravenous infusion of stem cells from donated newborn tissue is safe for people aged 4 to 39 with dilated cardiomyopathy (a weakened, enlarged heart). It aims to find a new option for those who haven't improved enough with standard heart failure medications.
Atlanta, GeorgiaAges 4–40 - NCT06455449RecruitingPhase 3
Injectable anifrolumab for polymyositis or dermatomyositis
This study tests a new injectable medicine (anifrolumab) added to your usual treatments for polymyositis or dermatomyositis. It may help reduce disease activity if you have moderate to severe symptoms and are already on stable therapy.
Phoenix, ArizonaAges 18–75 - NCT06447025RecruitingPhase 2
Study of CTI-1601 for people with Friedreich's ataxia
This trial tests an injectable medicine called CTI-1601 for Friedreich's ataxia (FRDA). It is an open-label study, meaning everyone knows they are getting the drug. The study is for people who have taken CTI-1601 before (without serious side effects) or are new to the drug.
Los Angeles, CaliforniaAges 2–60
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 366 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.